Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active ...
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?
The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the ...